Entera Bio (ENTX) Profit After Tax (2019 - 2026)

Entera Bio (ENTX) has 8 years of Profit After Tax data on file, last reported at -$3.5 million in Q1 2026.

• Quarterly Profit After Tax fell 36.54% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.4 million (down 22.65% YoY) and the FY2025 annual result came in at -$11.4 million, down 19.89% from the prior year.
• Profit After Tax retreated to -$3.5 million in Q1 2026, from -$3.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.0 million in Q4 2023 to a low of -$3.8 million in Q1 2022.
• A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 64.81% — and 2023, when it soared 42.12%.
• Tracing ENTX's Profit After Tax over 5 years: stood at -$3.0 million in 2022, then surged by 34.27% to -$2.0 million in 2023, then retreated by 18.2% to -$2.4 million in 2024, then declined by 27.91% to -$3.0 million in 2025, then slipped by 16.21% to -$3.5 million in 2026.
• The last three Profit After Tax figures came in at -$3.5 million (Q1 2026), -$3.0 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.